|
WO2006066089A1
|
|
Humanized amyloid beta antibodies for use in improving cognition
|
|
WO2006066233A1
|
|
An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
|
|
CA2571856A1
|
|
Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
|
|
AU2005200811A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
US2005059591A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
US2005059802A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
BRPI0407058A
|
|
Methods of prophylaxis and treatment of a disease, pharmaceutical composition, and use of a fragment
|
|
AU2772702A
|
|
Method of suppressing beta-amyloid-related changes in Alzheimer's disease
|
|
KR20070004139A
|
|
Humanized antibodies that recognize beta amyloid peptide
|
|
US6787637B1
|
|
N-Terminal amyloid-β antibodies
|
|
US6743427B1
|
|
Prevention and treatment of amyloidogenic disease
|
|
US6750324B1
|
|
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US6710226B1
|
|
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
|
US6913745B1
|
|
Passive immunization of Alzheimer's disease
|
|
HU0201410A2
|
|
Compositions of a-betha peptide and processes for producing same
|
|
US6923964B1
|
|
Active immunization of AScr for prion disorders
|
|
BR0011251A
|
|
A-beta peptide compositions and processes for producing them
|
|
US6761888B1
|
|
Passive immunization treatment of Alzheimer's disease
|
|
EP1033998A1
|
|
Suppressing beta-amyloid-related changes in alzheimer's disease
|
|
US6787523B1
|
|
Prevention and treatment of amyloidogenic disease
|
